Results 71 to 80 of about 1,483 (209)

Renal Paraganglioma: A Rare Case of Secondary Hypertension in a Young Patient

open access: yesJournal of Urological Surgery
Paragangliomas are catecholamine-secreting neuroendocrine tumors that form outside of the adrenal gland. A 19-year-old woman with a history of hypertension was found to have an incidental mass on the inferior right kidney on imaging after presenting to ...
Mitchell J. Finkelstein   +5 more
doaj   +1 more source

A New Method of Building Patients’ Health-Awareness in Uro-Oncology

open access: yesSociété Internationale d’Urologie Journal, 2023
BackgroundDespite vast scientific evidence supporting health-awareness in the prevention and treatment outcome of cancer, studies comparing the effectiveness of different educational methods in in raising patients’ health-awareness are lacking ...
Pawel Nalej   +4 more
doaj   +1 more source

Artificial intelligence assisted 3D in the robotic urooncology? A systematic review and narrative synthesis of current applications, challenges and future directions.

open access: yesThe Canadian journal of urology
BACKGROUND Artificial intelligence (AI)-assisted three-dimensional (3D) surgical platforms, integrated with augmented reality, have the potential to improve intraoperative anatomical recognition and provide surgeons with an immersive, dynamic operating ...
B. Barakat   +5 more
semanticscholar   +1 more source

Induction of SOX17 with stimulation of WNT, TGF‐beta, and FGF signaling drives embryonal carcinomas into the yolk‐sac tumor lineage resulting in increased cisplatin resistance

open access: yesInternational Journal of Cancer, Volume 156, Issue 11, Page 2210-2224, 1 June 2025.
What's new? Yolk‐sac tumor formation has been suggested to be an escape mechanism during therapy in patients with relapsing germ cell tumors. The molecular mechanisms inducing yolk‐sac tumor development from stem cell‐like precursor embryonal carcinomas remain unclear.
Mara Kotthoff   +11 more
wiley   +1 more source

Oncological outcomes of papillary versus clear cell renal cell carcinoma in pT1 and pT2 stage: Results from a contemporary Turkish patient cohort

open access: yes, 2023
OBJECTIVES: To compare overall survival (OS), recurrence free survival (RFS), and cancer-specific survival (CSS) in the long-term follow-up of T1 and T2 clear-cell-Renal Cell Carcinoma (ccRCC) and papillary Renal Cell Carcinoma (pRCC) patients, as well ...
TİNAY, İLKER
core   +2 more sources

Digital spatial profiling identifies the tumor center as a topological niche in prostate cancer characterized by an upregulation of BAD

open access: yesScientific Reports
Prostate cancer is characterized by a high degree of intratumoral heterogeneity. However, little is known about the spatial distribution of cancer cells with respect to specific functional characteristics and the formation of spatial niches.
Ann-Kathrin Huber   +10 more
doaj   +1 more source

Robot-assisted Radical Cystectomy with Orthotopic Neobladder (Pitcher Pot): Point of Technique

open access: yesJournal of Urological Surgery
Robot-assisted radical cystectomy with orthotopic neobladder reconstruction represents a significant advancement in the surgical management of muscle-invasive bladder carcinoma.
Gautam Shubhankar   +3 more
doaj   +1 more source

Trauma renal cerrado de alto grado: el rol de la angioembolización en el manejo secuencial

open access: yesUrología Colombiana, 2023
El trauma renal corresponde a un 10% de todos los traumas abdominales; de ellos, un 90% comprende el trauma cerrado.
María P. Gómez-Bueno   +1 more
doaj   +1 more source

Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle‐Invasive Bladder Cancer Treated With Radical Cystectomy

open access: yesCancer Medicine, Volume 14, Issue 9, May 2025.
ABSTRACT Objective To evaluate the effects of the number of neoadjuvant chemotherapy (NAC) cycles and the addition of adjuvant chemotherapy (AC) after NAC on overall survival (OS) of patients with muscle‐invasive bladder cancer (MIBC). Patients and Methods We retrospectively evaluated 1687 patients with cT2‐4NxM0 MIBC who received radical cystectomy ...
Shingo Hatakeyama   +40 more
wiley   +1 more source

The New Tumour Biomarker miRNA‐371‐3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines

open access: yesJournal of Cellular and Molecular Medicine, Volume 28, Issue 24, December 2024.
ABSTRACT Cisplatin is used to treat a variety of malignancies, including testicular germ cell tumours (TGCTs). Although cisplatin‐based chemotherapy yields high response rates, a subset of patients develop cisplatin resistance, limiting treatment options and worsening prognosis.
Richard Weiten   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy